Inverness Medical Innovations Inc. / Abbott Laboratories Rapid Diagnostics (pregnancy / drug-of-abuse lines)

Rapid Point-of-Care Diagnostics (Pregnancy & Drugs of Abuse)

Disease Overview

Rapid point-of-care (POC) diagnostics in this category cover at-home and clinic-based lateral-flow immunoassays for pregnancy detection (hCG) and screening for illicit drugs of abuse (cocaine, opiates, amphetamines, THC, etc.). They serve consumers, OB/GYN practices, urgent care, employers, and law enforcement, where speed and ease of use matter more than central-lab sensitivity.

Competitive Landscape

In the early-2000s rapid-diagnostics category, the consumer pregnancy test market was led by Procter & Gamble's Clearblue franchise (later Inverness/SPD JV) and Church & Dwight's First Response, with Abbott's Fact Plus and private-label e.p.t-style products as secondary brands. In professional rapid testing for strep, drugs of abuse, and pregnancy, Abbott's TestPack/TestPack Plus/Signify lines competed with Quidel, Beckman Coulter ICON, Roche, OraSure, and Biosite. Inverness Medical Innovations had been assembled out of the diagnostics carve-out left after Johnson & Johnson bought its glucose business in 2001, and was rolling up smaller diagnostics players (Applied Biotech, Ostex, Wampole) to build a women's-health and infectious-disease POC platform. The Abbott rapid-diagnostics asset purchase added recognized brands (Fact Plus, TestPack, Signify) and pulled a meaningful pregnancy/strep/drug-of-abuse competitor off the field, accelerating Inverness's path toward becoming Alere — the eventual POC consolidator that Abbott itself bought back in 2017. Strategically, the deal reset competitive dynamics: Abbott exited consumer/professional rapid Dx in these niches, and Inverness gained scale plus distribution leverage in retail pharmacy and physician-office channels.